Table 3.

Tolerance of ICI reintroduction

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7
Delay of resumption of ICI after meningitis (days)	373	54	24	118	4 (No ICI discontinuation)	126	19
ICI regimen at the rechallenge	Ipilimumab 1 mg/kg +nivolumab 3 mg/kg	Ipilimumab 1 mg/kg +nivolumab 3 mg/kg	Spartalizumab 400 mg	Nivolumab 3 mg/kg	Nivolumab 3 mg/kg	Spartalizumab 400 mg +ribociclib 600 mg/day	Nivolumab 3 mg/kg
Steroid treatment at the time of ICI resumption*	0.5 mg/kg/day	0	0	0	0	0	0
Meningitis recurrence	No	No	No	No	No	No	No
Other irAEs occurrence at rechallenge with ICIs	No	No	Interstitial lung disease (grade 3)	No	No	No	No
Cancer status at 3 months from rechallenge with ICIs	PD	PR	PD	PD	PR	PD	PR
Cancer status at latest follow-up (months from rechallenge)	Death caused by cancer progression	Maintained CR (32 months)	Maintained PR (25 months)	Death caused by cancer progression	Maintained PR (6 months)	Death caused by cancer progression	Maintained PR (17 months)

*Prednisone equivalent doses.

CR, complete response; ICI, immune-checkpoint inhibitor; irAE, immune-related adverse event; PD, progression disease; PR, partial response.